Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Comparative Analysis of Radioactive Iodine Versus Thyroidectomy for Definitive Treatment of Graves’ Disease
source: Surgery
year: 2017
authors: Wu VT, Lorenzen AW, Beck AC, Reid VJ, Sugg SL, Howe JR, Pollard JH, Lal G, Weigel RJ
summary/abstract:Background:
Management of Graves disease includes antithyroid drugs, 131I therapy, or thyroidectomy. Our aim was to review our institutional experience with definitive treatments for Graves disease.
Methods:
This was a retrospective review of patients undergoing 131I therapy (n = 295) or thyroidectomy (n = 103) for Graves disease (2003-2015). Demographic, clinical, pathology, and outcome data were collected from institutional databases.
Results:
131I therapy patients were older (39.1 years vs 33.4 years, P = .001). There was no difference in the presence of ophthalmopathy between groups. A larger proportion of children received thyroidectomy than 131I therapy (17.1% vs 9.2%, P = .026). The success rate of the first 131I therapy dose was 81.4%. Overall success rate, including additional doses, was 90.1%. Rapid turnover of iodine correlated with 131I therapy failure (58.3% rapid turnover failure vs 14.9% non-rapid turnover failure, P < .05). All surgical patients underwent total or near-total thyroidectomy. 131I therapy complications included worsening thyrotoxicosis (1%) and deteriorating orbitopathy (0.7%). Operative complications were higher than 131I therapy complications (P < .05) but were transient. There was no worsening orbitopathy or recurrent Graves disease among surgical patients.
Conclusion:
A higher proportion of pediatric Graves disease patients underwent thyroidectomy than 131I therapy. Rapid turnover suggested more effective initial management with operation than 131I therapy. Although transient operative complications were high, 131I therapy complications included worsening of Graves orbitopathy among those with pre-existing orbitopathy.
DOI: 10.1016/j.surg.2016.06.066
read more full text
Related Content
-
Kian Eftekhari, MDDr. Kian Eftekhari is an Oculofacial Pla...
-
Weight Gain After Treatment of Graves’ Disease in ChildrenObjective: The frequency of and risk fa...
-
Teprotumumab for the Treatment of Active Thyroid Eye DiseaseBackground: Thyroid eye disease is a de...
-
TEPEZZA Has Resumed Production – FAQHorizon Therapeutics, the developer of T...
-
Remission of Graves’ Disease During Anti-Thyroid Drug Therapy: Time to Reconsider the Mechanism?Therapy of Graves' hyperthyroidism with ...
-
Predicting Risk of Recurrent Thyrotoxicosis Following Thionamide Withdrawal in Graves’ DiseaseBackground/Aim: Thionamides are a safe ...
-
Mark Codner, MD (Deceased)Mark Codner was a Clinical Assistant Pro...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.